Quick charity verification for Karen Wyckoff Rein In Sarcoma (EIN: 200811343)
Verdict: Karen Wyckoff Rein In Sarcoma appears trustworthy
92/100Mission Score
$1.5MRevenue
$1.1MAssets
0Red Flags
5Strengths
No red flags identified.
Strengths
Consistent 0% officer compensation, indicating high efficiency and dedication to mission.
Strong asset growth from $387,852 in 2014 to $1,175,955 in 2023.
Generally operates with a financial surplus, contributing to asset accumulation (e.g., $51,871 surplus in 2023).
Consistent IRS 990 filing history (13 filings), demonstrating transparency.
Low liabilities relative to assets, indicating strong financial solvency (e.g., $15,280 liabilities vs. $1,175,955 assets in 2023).
Spending Breakdown
How Karen Wyckoff Rein In Sarcoma allocates its funds across programs, administration, and fundraising.
85%
Program Spending
Healthy — majority goes to mission
10%
Admin Costs
Reasonable — admin costs in check
5%
Fundraising
Within typical range
How to read this: Well-run charities typically spend 75% or more on programs, keep admin under 25%, and fundraising under 15%. A high program ratio means more of every dollar goes directly to the mission.
How to Interpret This Report
What Red Flags Mean
Red flags are potential warning signs identified by AI analysis of IRS 990 filings. They may indicate issues like declining revenue, high executive pay relative to program spending, lack of transparency, or governance concerns. A single red flag does not necessarily mean an organization is untrustworthy, but multiple flags warrant further investigation before donating.
What Mission Score Measures
The Mission Score (0-100) evaluates how effectively a nonprofit fulfills its stated purpose. It combines multiple factors: program spending efficiency (how much goes to programs vs. overhead), financial health and sustainability, governance quality, transparency in reporting, and consistency of operations over time. A score of 70+ indicates strong alignment with the organization’s mission.
Using This Data for Donation Decisions
Use this report as one input in your decision. Look at the overall Mission Score for a quick assessment, review red flags and strengths for specific concerns, check the spending breakdown to see where money goes, and compare executive compensation to the organization’s size. Consider viewing the full transparency report for deeper analysis, and always verify tax-exempt status with the IRS before making large donations.
Frequently Asked Questions about Karen Wyckoff Rein In Sarcoma
Is Karen Wyckoff Rein In Sarcoma a legitimate charity?
Based on AI analysis of IRS 990 filings, Karen Wyckoff Rein In Sarcoma (EIN: 200811343) appears trustworthy. Mission Score: 92/100. 0 red flags identified, 5 strengths noted.
Is Karen Wyckoff Rein In Sarcoma a good charity to donate to?
Karen Wyckoff Rein In Sarcoma has a Mission Score of 92/100. Revenue: $1.5M. Assets: $1.1M. Review the full transparency report for detailed spending breakdown and executive compensation analysis.
What is the EIN for Karen Wyckoff Rein In Sarcoma?
The Employer Identification Number (EIN) for Karen Wyckoff Rein In Sarcoma is 200811343. This is the unique tax ID assigned by the IRS.
What is a Mission Score?
The Mission Score is a 0-100 rating that measures how effectively a nonprofit fulfills its stated mission. It factors in program spending efficiency, financial transparency, governance practices, and outcome reporting. Scores above 70 indicate strong mission alignment, 40-69 suggest mixed performance, and below 40 signals potential concerns.
How does Karen Wyckoff Rein In Sarcoma spend its money?
Karen Wyckoff Rein In Sarcoma allocates 85% to programs, 10% to administration, and 5% to fundraising. Healthy nonprofits typically spend 75%+ on programs.
How can I verify Karen Wyckoff Rein In Sarcoma's tax-exempt status?
You can verify Karen Wyckoff Rein In Sarcoma's tax-exempt status using EIN 200811343 on the IRS Tax Exempt Organization Search (TEOS) at apps.irs.gov/app/eos. You can also request copies of their Form 990 directly from the organization, as they are required by law to provide them upon request.
AI Transparency Report
Karen Wyckoff Rein In Sarcoma demonstrates a generally healthy financial position with consistent revenue generation and asset growth over the past decade. The organization's latest reported revenue of $606,354 in 2023, with expenses of $554,483, indicates a surplus, contributing to its robust asset base of $1,175,955. While there was a slight dip in assets from $1,199,056 in 2022, the overall trend shows responsible financial management and accumulation of resources to support its mission. The organization's consistent reporting of 0% officer compensation across all filings suggests a strong commitment to directing funds towards programs rather than executive salaries, enhancing its spending efficiency and transparency.
The organization's financial health appears stable, with assets consistently exceeding liabilities, indicating good solvency. The absence of officer compensation is a significant positive indicator of efficiency and a focus on mission-driven spending. The consistent filing of IRS Form 990s over 13 periods also points to a high level of transparency and adherence to regulatory requirements, allowing for public scrutiny of its financial operations. This consistent reporting and lack of executive compensation contribute to a positive assessment of its financial stewardship.